#### **Advances in Bioresearch**

Adv. Biores., Vol 16 (5) September 2025: 163-167 ©2025 Society of Education, India Print ISSN 0976-4585; Online ISSN 2277-1573 Journal's URL:http://www.soeagra.com/abr.html CODEN: ABRDC3 DOI: 10.15515/abr.0976-4585.16.5.163167

Advances in Bioresearch

# **ORIGINAL ARTICLE**

# Analytical Method Development and Validation of UV-Visible Spectrophotometric Method for the Estimation of Solriamfetol in bulk and tablet formulation

# Sunil Kakad\*, Siddhi Sane and Anagha Joshi

<sup>1</sup> Department of Pharmaceutical Chemistry, Shree Chanakya Education Society's Indira College of Pharmacy, Pune

Corresponding Author: Email: sunil.kakad21@gmail.com

#### **ABSTRACT**

A new, accurate, precise, specific, robust, and first UV spectrophotometric approach for assessing the recently approved by FDA drug Solriamfetol, a first-in-class dopamine and norepinephrine reuptake inhibitor, in bulk and tablet dosage form, was developed and validated as per ICH norms. The UV spectrophotometric observations were taken at 257 nm and water was used as a diluent. The validation of the method was carried out in compliance with the ICH guidelines, and parameters such as linearity, accuracy, precision, limit of detection, limit of quantification, and robustness were evaluated. The linear calibration curve was observed across the concentration range of  $100\text{-}500\mu\text{g/ml}$  and with correlation coefficient of  $r^2 = 0.9998$ . The accuracy of developed method was indicated through percentage recovery study of drug which was found to be  $99.63\pm0.8088\%$ . The limit of detection and limit of quantitation was demonstrated as  $13.72\mu\text{g/ml}$  and  $41.58\mu\text{g/ml}$  respectively. Results have demonstrated that the procedure is accurate and precise, with relative standard deviation less than 2%, yet also being easy and economical. This new and simple UV spectrophotometric method can be easily implemented for routine estimation of the drug from bulk and pharmaceutical tablet dosage form with no interference from excipients. The study shown that the proposed method can be applied in conventional analysis.

Keywords: Solriamfetol, Sunosi, UV spectrophotometric method, Validation, Narcolepsy, Obstructive sleep apnea.

Received 15.06.2025 Revised 09.07.2025 Accepted 14.09.2025

#### How to cite this article:

Sunil K, Siddhi Sane and Anagha Joshi. Analytical Method Development and Validation of UV-Visible Spectrophotometric Method for the Estimation of Solriamfetol in bulk and tablet formulation. Adv. Biores., Vol 16 (5) September 2025: 163-167.

# INTRODUCTION

Solriamfetol, which is currently marketed under the Sunosi ® brand, received FDA approval in March 2019. The solriamfetol is a phenylalanine derivative with the chemical formula (R)-2-amino-3-phenylpropylcarbamate hydrochloride (Figure 1). Solriamfetol is a distinct, approved by the FDA enantiopure drug intended to treat excessive daytime drowsiness caused by obstructive sleep apnea or narcolepsy. R- Solriamfetol, that is only the active R-enantiomer is marketed as a norepinephrine and dopamine reuptake inhibitor for the treatment of daytime drowsiness caused by narcolepsy or obstructive sleep apnea [1]. Solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its kind to be evaluated by the USFDA for the treatment of excessive drowsiness in Obstructive sleep apnea and narcolepsy patients. Sleep-wake regulation relies heavily on monoaminergic systems (serotonin, norepinephrine, and dopamine). Solriamfetol can selectively bind to and block reuptake at dopamine and norepinephrine transporters while without increasing monoamine release [2]. The objective of the current study was to develop accurate, reproducible UV spectroscopic approach for detection of the solriamfetol in bulk and pharmaceutical formulation. The method was evaluated for parameters like linearity, accuracy, precision, robustness, LOD, and LOQ in accordance with ICH recommendations.




Fig 1: Solriamfetol Structure

#### **MATERIAL AND METHODS**

#### **Instruments:**

The Jasco V-730 double beam UV Spectrophotometer, with matching 1 cm path length quartz cells and weighing balance Shimadzu A×200 was used for this work.

#### Materials:

The Solriamfetol pure drug was obtained from Alkem Laboratories, Mumbai. The distilled water used was obtained from institute water purification system.

# Preparation of standard stock solution of solriamfetol:

The Standard stock solution of Solriamfetol is prepared by weighing 100 mg of Solriamfetol accurately and then was transferred to 100 ml volumetric flask. Then, volume was made up with distilled water to make  $1000 \, \mu \text{g/ml}$  or  $1 \, \text{mg/ml}$  solution.

# **Determination of wavelength of maximum absorption:**

Using distilled water as a blank solution the  $500\mu g/ml$  Solriamfetol solution was scanned in UV range of 200-400 nm. The wavelength of maximum absorbance was found to be 257 nm and is selected as an analytical wavelength. The UV spectrum of Solriamfetol is given in figure 2.




Fig 2: UV Spectrum of Solriamfetol

#### Preparation of Calibration Graph:

For the calibration graph, 1-5 ml aliquots from stock solution of Solriamfetol ( $1000\mu g/ml$ ) were transferred into 10 ml volumetric flask in sequence. The volume was made up with distilled water to get  $100\text{-}500~\mu g/ml$  solutions. At 257nm absorbances were taken and calibration curve was plotted as concentration vs Absorbance.

Table 1: Parameters for Calibration curve

| Concentration | Absorbance |  |  |
|---------------|------------|--|--|
| (μg/ml)       |            |  |  |
| 100           | 0.08219    |  |  |
| 200           | 0.16223    |  |  |
| 300           | 0.24023    |  |  |
| 400           | 0.32546    |  |  |
| 500           | 0.40250    |  |  |




Fig 3: Calibration curve of Solriamfetol

# Method Validation Of developed UV Spectrophotometric method Linearity:

The linearity of an analytical method refers to the method's ability to produce test outcomes that are directly proportional to the concentration of analyte in sample. The calibration curve was created for the concentration range of  $100\text{-}500\mu\text{g/ml}$ . The coefficient of correlation and linear regression equation were obtained.

#### **Accuracy:**

The analytical method's accuracy shows the degree of closeness of agreement between the accepted value (a conventional actual value or an approved reference value) and the value found. The accuracy of developed method is indicated by % recovery of Solriamfetol by standard addition method. The standard Solriamfetol and In-house prepared tablet formulation was used for this investigation. The dilutions were prepared at three concentration levels 80%, 100% and 120% of standard solution in known quantity of sample.

# **Precision:**

The precision of an analytical process represents the degree of closeness between a set of observations recorded from several samplings of the homogeneous sample under the specified conditions. The developed method was indicated for its precision based on Intra-day and Inter-day variation study. For the intra-day precision study three different solutions of concentration 100, 300,  $500\mu g/ml$  were prepared in triplicate (n=3) and analysed on same day. For Inter-day precision study three solutions were prepared in triplicate of concentrations 100, 300,  $500\mu g/ml$  and analysed on two different days. The mean, standard deviation and % RSD were calculated.

# Limit of Detection (LOD) and Limit of Quantitation (LOQ):

The Limit of Detection (LOD) of analytical procedure is the lowest amount of the analyte in the sample that can be detected but not exactly quantified. The Limit of Quantitation of analytical procedure is the lowest amount of analyte in the sample that can be detected and quantified.

$$LOD = 3.3 \times \sigma$$
S

$$LOQ = \frac{10 \times \sigma}{S}$$

Where,  $\sigma$  is the mean standard deviation of absorbances of sample solutions of calibration graph and S is the slope of the related calibration curve equation.

#### Robustness:

The ability of analytical method to obtain the repeatability in test results under the deliberate changes in method parameters is known as robustness. The robustness of the developed method was indicated by switching the analysts. The data was obtained as mean, standard deviation and % RSD.

#### RESULT AND DISCUSSION

# $\label{lem:continuous} \textbf{Method Validation of developed UV spectrophotometric method:}$

#### Linearity:

The linearity of developed method is demonstrated by triplicate analysis of five concentrations in range of  $100\text{-}500\mu\text{g/ml}$  concentrations. The calibration curve shows the linear relationship between concentration and absorbance in rage of  $100\text{-}500\mu\text{g/ml}$  with correlation coefficient of 0.9998 and regression equation as Y = 0.0008 X + 0.0014.

# Accuracy:

The accuracy was established in triplicate by analyzing the percentage recovery of Solriamfetol using the standard addition procedure. The data for the % recovery and % RSD was obtained. The % recovery obtained demonstrates that there is no interference from the excipients included in the formulation. The % RSD was found to be within the limit of less than 2 %. The table no.2 Shows the data for the accuracy.

Table 2: Data for Accuracy recovery study

| Level Of Addition (%) | Standard API<br>(µg/ml) | Formulation<br>Stock<br>(µg/ml) | Total Conc.<br>(μg/ml) | Drug<br>Recovered<br>(µg/ml) | %Recovery | %RSD |
|-----------------------|-------------------------|---------------------------------|------------------------|------------------------------|-----------|------|
| 80 %                  | 200                     | 160                             | 360                    | 354.6                        | 98.50     | 88.0 |
| 100 %                 | 200                     | 200                             | 400                    | 397.2                        | 99.30     | 0.69 |
| 120 %                 | 200                     | 240                             | 440                    | 444.8                        | 101.09    | 0.85 |

#### **Precision:**

The Intra-day and Inter-day precision were demonstrated in terms of calculated %RSD. For Intra-day precision, 100, 300, 500  $\mu$ g/ml concentration solutions were measured three times in a day and % RSD was calculated. For Inter-day precision the observations were measured on two different days and %RSD was calculated. The %RSD calculated were in specified limit of less than 2%. The data for the precision is shown in Table No.3 and 4.

**Table 3: Inter-Day precision** 

| 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 |                 |                    |      |  |  |
|---------------------------------------|-----------------|--------------------|------|--|--|
| Drug Concentration (µg/ml)            | Mean Absorbance | Standard deviation | %RSD |  |  |
| 100                                   | 0.08289         | 0.00010            | 0.12 |  |  |
| 300                                   | 0.2379          | 0.0012             | 0.53 |  |  |
| 500                                   | 0.3997          | 0.0024             | 0.60 |  |  |

**Table 4: Intra-Day Precision** 

| Drug Concentration (μg/ml) | Mean Absorbance | Standard deviation | %RSD |
|----------------------------|-----------------|--------------------|------|
| 100                        | 0.08269         | 0.00020            | 0.24 |
| 300                        | 0.2375          | 0.0031             | 1.32 |
| 500                        | 0.3964          | 0.0038             | 0.98 |

# Limit of Detection (LOD) and Limit of Quantification (LOQ):

The method sensitivity parameters like limit of detection (LOD) and Limit of Quantitation were estimated with help of calibration curve. The limit of detection and limit of quantitation were estimated to be 13.72  $\mu$ g/ml and 41.58  $\mu$ g/ml respectively.

# Robustness:

The robustness was indicated based on the %RSD values for the observations obtained by the switching between the analysts. The %RSD was observed to be less than 2 %. The data is given in Table no 5.

**Table 5: Robustness** 

| Drug<br>Concentration<br>(μg/ml) |                 | Analyst<br>1 |                | Analyst<br>2   |      |                      |
|----------------------------------|-----------------|--------------|----------------|----------------|------|----------------------|
|                                  | Mean abs ± SD   | %RSD         | % Amount found | Mean abs ± SD  | %RSD | %<br>Amount<br>found |
| 100                              | 0.08202±0.00061 | 0.75         | 102.5          | 0.08245±0.0002 | 0.24 | 103                  |
| 300                              | 0.23463±0.0041  | 1.76         | 97.7           | 0.2411±0.0021  | 0.87 | 100                  |
| 500                              | 0.3941±0.0027   | 0.68         | 98.5           | 0.4002±0.0012  | 0.31 | 100                  |

#### CONCLUSION

The UV-Spectrophotometric method was developed for determination of Solriamfetol from pure drug and its formulation. The developed method was validated in accordance with the guidelines referring to ICH Q2 (R1). The method was found to be simple, Precise, accurate and reproducible for estimation of Solriamfetol. The method is economic and environmentally friendly because of use of water as a diluent. This method can be effectively utilized for the routine analysis of Solriamfetol in quality control laboratories.

#### REFERENCES

- 1. Köteles I, Foroughbakhshfasaei M, Dobó M, Ádám M, Boldizsár I, Szabó ZI, Tóth G. (2020): Determination of the enantiomeric purity of solriamfetol by high-performance liquid chromatography in polar organic mode using polysaccharide-type chiral stationary phases. Chromatographia. Jul; 83:909-13.
- 2. Yang J, Gao J. (2019): Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Review of Clinical Pharmacology. Aug 3;12(8):723-8.
- 3. Yang J, Gao J. (2019): Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Review of Clinical Pharmacology. Aug 3;12(8):723-8.
- 4. Abad VC, Guilleminault C. (2018): Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea. Expert Review of Respiratory Medicine. Dec 2;12(12):1007-19.
- 5. Zadbuke N, Shahi S, Jadhav A, Borde S. (2016): Development and validation of UV-visible spectroscopic method for estimation of carbamazepine in bulk and tablet dosage form. Int J Pharm Pharm Sci.;8(2):234-8.
- 6. Vaishali Pardeshi, Tushar Lokhande, Rina Firke, Sneha Patil, Vishakha Pawar (2023): Development and Validation of a simple UV spectrophotometric method for the determination of Delamanid. Int. J. Res. Pharm. Sci.;14(1):10-4.

**Copyright:** © **2025 Author**. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.